<DOC>
	<DOC>NCT00457795</DOC>
	<brief_summary>This study will evaluate the efficacy and safety of brimonidine 0.1% three-times daily in patients with glaucoma or ocular hypertension</brief_summary>
	<brief_title>24-hour IOP-lowering Effect of Brimonidine 0.1%</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<criteria>patients with openangle glaucoma or ocular hypertension allergy to brimonidine inability to complete 24 hour stay for monitoring</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>